Holy Cross Hospital
- Type
- Teaching hospital
- Where
- Silver Spring, MD
- Medicare CCN
- 210004
- Received
- $392,368 in 25 records, 2024 ($1,023 general, $391,345 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: HOLY CROSS HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: HOLY CROSS HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 2 | $1,023 |
| 2024 | Research payment | 23 | $391,345 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $288,175 | 2024 |
| Daiichi Sankyo Inc. | 3 | $55,243 | 2024 |
| ABBVIE INC. | 1 | $27,240 | 2024 |
| Medtronic, Inc. | 7 | $8,457 | 2024 |
| GlaxoSmithKline, LLC. | 2 | $7,852 | 2024 |
| AstraZeneca UK Limited | 2 | $4,376 | 2024 |
| Cochlear Americas | 1 | $973 | 2024 |
| Abbott Laboratories | 1 | $50 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 23 | $391,345 |
| Long term medical supply or device loan | 1 | $973 |
| Space rental or facility fees (teaching hospital only) | 1 | $50 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $187 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2024 |
| 2024-12-31 | AstraZeneca UK Limited | $98 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertini | 2024 |
| 2024-12-12 | Daiichi Sankyo Inc. | $1,132 | Research payment | Cash or cash equivalent | DS8201-A-U305 | 2024 | |
| 2024-12-11 | Cochlear Americas | $973 | Long term medical supply or device loan | In-kind items and services | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2024 | |
| 2024-12-09 | ABBVIE INC. | $27,240 | Research payment | Cash or cash equivalent | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants Wit | 2024 | |
| 2024-12-05 | AstraZeneca UK Limited | $4,278 | Research payment | Cash or cash equivalent | A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Ad | 2024 | |
| 2024-12-05 | GlaxoSmithKline, LLC. | $1,970 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2024 | |
| 2024-11-07 | Medtronic, Inc. | $416 | Research payment | Cash or cash equivalent | SYNCHROMEDII Device, Drug Infusion Systems | PSR-TDD | 2024 |
| 2024-08-26 | Medtronic, Inc. | $1,029 | Research payment | Cash or cash equivalent | SYNCHROMEDII Device, Drug Infusion Systems | PSR-TDD | 2024 |
| 2024-08-26 | Medtronic, Inc. | $397 | Research payment | Cash or cash equivalent | INTELLIS ADAPTIVESTIM Device, Spinal Cord Neurostimulation | PSR-PSTM | 2024 |
| 2024-08-08 | Daiichi Sankyo Inc. | $26,521 | Research payment | Cash or cash equivalent | DS8201-A-U305 | 2024 | |
| 2024-05-16 | Medtronic, Inc. | $1,831 | Research payment | Cash or cash equivalent | SYNCHROMEDII Device, Drug Infusion Systems | PSR-TDD | 2024 |
| 2024-05-16 | Medtronic, Inc. | $919 | Research payment | Cash or cash equivalent | INTELLIS ADAPTIVESTIM Device, Spinal Cord Neurostimulation | PSR-PSTM | 2024 |
| 2024-04-26 | AstraZeneca Pharmaceuticals LP | $5,352 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durva | 2024 |
| 2024-04-05 | AstraZeneca Pharmaceuticals LP | $29,880 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2024 |
| 2024-04-01 | Abbott Laboratories | $50 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMPLATZER Device, Structural Heart | 2024 | |
| 2024-03-29 | Daiichi Sankyo Inc. | $27,589 | Research payment | Cash or cash equivalent | DS8201-A-U305 | 2024 | |
| 2024-03-25 | GlaxoSmithKline, LLC. | $5,882 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2024 | |
| 2024-03-13 | AstraZeneca Pharmaceuticals LP | $13,260 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the effica | 2024 |
| 2024-02-15 | Medtronic, Inc. | $2,667 | Research payment | Cash or cash equivalent | SYNCHROMEDII Device, Drug Infusion Systems | PSR-TDD | 2024 |
| 2024-02-15 | Medtronic, Inc. | $1,196 | Research payment | Cash or cash equivalent | INTELLIS ADAPTIVESTIM Device, Spinal Cord Neurostimulation | PSR-PSTM | 2024 |
| 2024-01-24 | AstraZeneca Pharmaceuticals LP | $187,152 | Research payment | Cash or cash equivalent | ENHERTU Biological, Oncology | An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as fir | 2024 |
| 2024-01-19 | AstraZeneca Pharmaceuticals LP | $19,132 | Research payment | Cash or cash equivalent | Truqap Drug, Oncology | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo | 2024 |
| 2024-01-17 | AstraZeneca Pharmaceuticals LP | $1,250 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2024 |
| 2024-01-05 | AstraZeneca Pharmaceuticals LP | $31,960 | Research payment | Cash or cash equivalent | A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Silver Spring, MD, county Montgomery County, MD, state Maryland; placed by its city name.
| Measure | Place (city or town) Silver Spring, MD | County Montgomery County, MD | State Maryland |
|---|---|---|---|
| Population B01003 | 81,462 | 1,065,949 | 6,206,011 |
| Population, 2020 census P1 | 81,015 | 1,062,061 | 6,177,224 |
| Median age B01002 | 35.6 | 40.2 | 39.4 |
| Under 18 B01001 | 22.2% | 22.8% | 22.2% |
| 65 and over B01001 | 12.1% | 17.0% | 16.7% |
| Households B11001 | 33,988 | 389,210 | 2,362,928 |
| Foreign born B05002 | 33.9% | 33.6% | 16.6% |
| Median household income B19013 | $99,860 | $132,450 | $103,678 |
| Median family income B19113 | $126,101 | $164,096 | $127,817 |
| Per capita income B19301 | $57,635 | $67,571 | $52,979 |
| Poverty rate B17001 | 10.6% | 7.5% | 9.4% |
| Unemployment rate B23025 | 5.4% | 4.9% | 4.9% |
| Civilian labor force B23025 | 50,814 | 590,776 | 3,313,651 |
| Mean commute (minutes) B08013 | 34.0 | 31.9 | 31.1 |
| Bachelor's degree or higher B15003 | 60.6% | 60.6% | 43.4% |
| Housing units B25001 | 35,774 | 406,531 | 2,560,784 |
| Owner-occupied B25003 | 38.3% | 65.3% | 67.6% |
| Renters B25003 | 61.7% | 34.7% | 32.4% |
| Median home value B25077 | $643,300 | $640,300 | $419,900 |
| Median gross rent B25064 | $1,913 | $2,068 | $1,705 |
| White, not Hispanic B03002 | 32.8% | 39.5% | 46.6% |
| Black B03002 | 28.3% | 18.3% | 28.9% |
| Hispanic or Latino B03002 | 24.5% | 21.0% | 12.5% |
| Asian B03002 | 8.5% | 15.3% | 6.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Silver Spring, MD.
Comments